Back to News
Feb 5, 2026 8:01 AM

Angitia Biopharmaceuticals Announces $130 Million Series D Financing

- Financing co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners with significant participation from other new and existing investors

- Proceeds will support the ongoing clinical development of AGA2118, AGA2115, AGA111, and other pipeline assets

- Kevin Li, M.D., from Frazier Life Sciences will join the Board of Directors

WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) --  Angitia Biopharmaceuticals ("Angitia" or "the Company"), a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health, today announced the closing of a $130 million Series D financing round. Frazier Life Sciences and Venrock Healthcare Capital Partners co-led the financing, with participation from new investors: Ascenta Capital, certain funds and accounts managed by Blackrock, BVF Partners, Logos Capital, RA Capital Management, and Wellington Management. Existing investors, Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment, Hillhouse Investment, Legend Capital, Morningside Group, OrbiMed, TF Capital and Yonghua Capital, also participated. Proceeds from the Series D will support the continued development of Angitia's robust pipeline of novel, differentiated investigational treatments for serious musculoskeletal diseases.

"This financing underscores the continued growth of Angitia, the quality of our emerging data, and the advancement of our clinical product candidates, as ...